Disclosures

• I am Director of the ECFS Clinical Trial Network

• I have not received any fees or payments from Pharma related to CF Therapies

• I am subject to several confidentiality agreements with different Pharma related to Protocol Review and Feasibility activity for ECFS-CTN related to this topic

• Data I present today is all in the public domain
Overview of CFTR Modifier Pipeline

- ClinicalTrials.gov
- 60 studies involve CFTR modulators

Tim Lee, United Kingdom
ECFS-CTN Director
### CFTR Mutation Classes

- **Normal**

- **Class 1** Stop mutations

- **Class 2** (phe508del) Defective Processing

- **Class 3** (G551D) Defective regulation

- **Class 4** Defective conductance

- **Class 5** Reduced synthesis

### Approach

- **Corrector** (or suppressor of premature termination eg Ataluren) ? also potentiator??

- **Corrector** eg VX 809/VX 661/Riociguat/N91115/inhaled QR-010 ? with potentiator eg Orkambi™

- **Potentiator** eg Ivacaftor, QBW251

- **Potentiator** eg Ivacaftor, QBW251

- **Rare**: Corrector? ?QBW251

*Images from Johns Hopkins Medicine CME “Ahead of the Curve”*
Serious CF extra pulmonary manifestations

- Pancreatic insufficiency  
  approx 90% of people with CF
- CF Liver disease in up to 41%  
  Cirrhosis in 7.8%, transplant 2%  
  Lamireau et al J of Hepatology 2004
- CF related diabetes  
  2% of children, 19% of adolescents, and 40-50% of adults  
  Dunitz 2009; 32 (9): 1626-31
Geographical distribution of phe508del mutation in Europe

Spatial patterns of cystic fibrosis mutation spectra in European populations
Lao O et al.
VX-809 (Lumacaftor) plus VX-770 (Kalydeco™, Ivacaftor) for phe508del/phe508del
Phase 3: Orkambi™

- 2 large double blind RCTs (TRAFFIC and TRANSPORT)
- 1108 patients (mean baseline FEV1 = 61% pred)
- Lumacaftor (600 mg once daily or 400 mg every 12 hours) in combination with ivacaftor (250 mg every 12 hours) or matched placebo for 24 weeks
- Primary end point: Absolute change from baseline in % predicted FEV1 at week 24

Wainwright C et al. 2015: Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for the phe508del CFTR.
NEJM DOI: 10.1056/NEJMoa1409547
VX-809 (Lumacaftor) plus VX-770 (Kalydeco™, Ivacaftor) for phe508del/phe508del Phase 3: Orkambi™

Range from 2.6 to 4 percentage points
P<0.001 for all comparisons
Change by Day 15, sustained through 24w
Seen in all subgroups including FEV1 <40%

3.2% improvement over placebo
P=0.006
Change by Day 28, sustained through 96w
Younger patients (8 years, FEV1 95%)

Wainwright C et al. 2015: Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for the phe508del CFTR. NEJM DOI: 10.1056/NEJMoa1409547

Quan JM et al. 2001: A two year randomised placebo-controlled trial of Dornase-alpha in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatrics 139: 813-20
VX-809 (Lumacaftor) plus VX-770 (Kalydeco™, Ivacaftor) for phe508del/phe508del Phase 3: Orkambi™

30-39% reduction in pulmonary exacerb. P= and <0.001 respectively
45-56% reduction in requirement for iv antibiotics P < 0.001

Wainwright C et al. 2015: Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for the phe508del CFTR.
NEJM DOI: 10.1056/NEJMoa1409547

34% reduction in RTE P=0.048
RTE= Resp symptoms req. iv antibiotics Younger patients (8 years, FEV1 95%)

Quan JM et al. 2001: A two year randomised placebo-controlled trial of Dornase-alpha in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatrics 139: 813-20
What do we know about VX-661 plus Ivacaftor Combination Programme?

- 39 adults with 2 copies phe508del
- Mean within-group absolute improvement from baseline in %pred FEV1 of 4.4 percentage points (p=0.009) at week 4 and 3.0 (p=0.026) at week 12
- Pulmonary exacerbation occurred in 38% of patients who received VX-661 and 44 percent of those who received placebo (NS)
- Moving on to four Phase 3 studies:
  - People with two copies of the F508del mutation (began enrollment in February)
  - People with one F508del mutation and a second gating mutation (Class 3)
  - People with one F508del mutation and a second residual function mutation (Class 4)
  - People with one F508del mutation and a second mutation that results in minimal CFTR function (eg Class 1, Class 2)
Mean increase in faecal elastase 99.8 ug/g at 24 weeks, 101.9 after 72 weeks
34.6 of patients PI at baseline had one or more value >200 ug/g

Mean reduction in IRT (marker of pancreatic stress) of 20.7 ng/ml after 24 weeks.
What about CF patients with rare mutations?

• Organoids appear a good personalized predictor of response to CFTR modulator therapies.

• For people with CF who have rare mutations then n of 1 /very small number studies using organoid results as screening criteria seems a very appropriate and feasible way forward.

• We have a responsibility to consider carefully how people with rare mutations are not excluded from eventual access to better treatments for CF.

*Dekkers et al.*

Challenges/Opportunities

• Assessing efficacy in children
• People with rare CF mutations – need for n of 1 methodology
• Assessing improved CFTR modifiers over and above existing approved CFTR modifiers that become “standard of care”
• Addressing other important CFTR related disease especially gastro-intestinal, liver, pancreas, CF Related Diabetes.